Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 7Ovarian Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Multiple Myeloma 2Mouth Neoplasms 2Lymphoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

ipatasertib 1Telemedicine 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Hysterectomy 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × ipatasertib × 1 year × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡